Indiana’s growing partnership with Portugal includes imports like rubber, plastics and chemicals, the latter of which is driven largely by pharmaceuticals, according to a Portuguese trade representative.
Mehmet Oz, head of the Centers for Medicare and Medicaid Services, said talks over the price of weight-loss drugs are still ongoing.
The test—developed in collaboration with Eli Lilly and Co.—does not diagnose Alzheimer’s but is designed to rule out the presence of the disease’s pathology early on, or indicate further diagnostics are needed.
Indianapolis-based Eli Lilly and Co. said the investment will strengthen its manufacturing and supply capabilities to support its growing portfolio of drugs.
Shares in Indianapolis-based Eli Lilly and Co. were on the rise Wednesday after President Trump suggested the company would be next up to cut a deal over drug pricing.
The announcements are part of an effort to secure “Most Favored Nation” pricing deals with pharmaceutical manufacturers, an effort to link U.S. drug prices to the lowest cost of drugs paid by the wealthiest countries.
President Donald Trump’s announcement that his administration will impose a 100 percent tariff on patented pharmaceutical products sparked confusion Friday, as government officials, drug companies and trade groups sought clarity on how the levy would be applied.
The $6.5 billion Houston-area plant is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
Demand for obesity treatments has soared recently, due to unprecedented weight loss provided by regular injections of market leaders Wegovy from Novo Nordisk and Zepbound from Indianapolis-based Eli Lilly and Co.
Eli Lilly and Co. this month launched a public awareness campaign called Brain Health Matters, which features actress Julianne Moore urging people to be proactive as they age to lower their risk of dementia, including Alzheimer’s disease.
Ahead of decisions by the FDA, both Novo Nordisk and Eli Lilly are readying production for their weight-loss pills, having been unable to keep up with demand for their shots that exploded in popularity.
Eli Lilly and Co. and Novo Nordisk have been locked in a fierce battle to control the obesity market, which is projected to reach $100 billion by the end of the decade.
The Food and Drug Administration on Tuesday posted more than 100 letters to various drug and online prescribing companies, including Hims & Hers, which has built a multibillion-dollar business centered on lower-cost versions of blockbuster obesity injections.
Indianapolis-based Lilly said the new plant would create more than 650 jobs in Virginia for engineers, scientists, operations personnel and lab technicians, as well as 1,800 construction jobs.
The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs.
The recommendation applies to a range of GLP-1 drugs that also includes Novo Nordisk’s Ozempic and Lilly’s older diabetes treatment, Trulicity.
Eli Lilly and Co. announced this month it would raise the weight-loss treatment’s price by as much as 170%, presenting pharmacies with a dilemma about how much they would pass on to patients.
The company’s shares rose as much as 4.3% Tuesday after Eli Lilly announced the trial results for orforglipron.
Indianapolis-based Eli Lilly and Co. has operated in Ireland since the late 1970s and has more than 3,500 employees there.
Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes and obesity.
